Mesenchymal Stem Cells (MSCs)

Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are advantageous over other stem cells types for a variety of reasons. First, they avoid the ethical issues that surround embryonic stem cell research.

Second, repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogeneic transplantation. MSCs reduce both the risks of rejection and complications of transplantation.

Third, there have been advances in the use of umbilical cord mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, and bone fractures, because MSCs can exert regenerative effects through homing to sites of damage, paracrine signaling, regulating the immune response, and affecting the microenvironment.

In combination, these traits make Mesenchymal stem cells of intense therapeutic interest, because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.

Mesenchymal Stem Cells have a range of benefits compared to other stem cell types, as presented below:

  1. Well-characterized: Mesenchymal stem cells are a well-characterized population of adult stem cells, with over 36,000 scientific articles published about them.
  2. Non-Controversial: Mesenchymal stem cells avoid the ethical issues of embryonic stem cells, as they can be derived from sources that include adult bone marrow and adipose tissue.
  3. Diverse Differentiation Potential: Mesenchymal stem cells can form a variety of cell types in the laboratory, including those of both intra- and extra-mesenchymal lineage. These cell types include fat (adipocytes), bone (osteoblasts), skin (dermal cells), nerve (neural cells), cartilage (chondrocytes), muscle (skeletal myocytes), tendons (tenocytes), marrow stroma, ligaments, and more.
  4. Ease of Growth in Culture: Advanced knowledge exists for how to grow Mesenchymal stem cells in culture, including protocols for isolation, expansion, and differentiation.
  5. Flexible Propagation: Mesenchymal stem cells can be grown and propagated in culture for extended periods, without losing differentiation potential.
  6. Role as Regulatory Cells: Mesenchymal stem cells synthesize and secrete a variety of macromolecules that are known regulators of hematopoietic and bone-resorbing cells.
  7. Favorable Immune Status: Mesenchymal stem cells lack the co-stimulatory molecules of the B7 family that are required to initiate an immune response. This allows the administration of MSC preparations across MHC barriers without concern for immunological rejection or the need for immunosuppression, making Mesenchymal stem cells a universal stem cells source.

Mesenchymal Stem Cell Therapy from the Umbilical Cord

 

Mesenchymal stem cells are early passage multipotent progenitor cells derived from human cord tissue that are capable of supporting hematopoiesis and differentiating into multiple lineages (osteogenic, adipogenic, chondrogenic, neurogenic, myogenic, and cardiomyogenic.)

For acceptance: Maternal blood and cord blood is tested negative for HIV I&II, HCV, CMV IgG/IgM, syphilis IgG/IgM antibodies and Hepatitis B surface antigen. Free of bacterial and fungal contamination.

Mesenchymal stem cells (MSCs) are advantageous over other stem cells types for a variety of reasons. First, they avoid the ethical issues that surround embryonic stem cell research.

Second, repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogeneic transplantation.

Third, there have been advances in the use of umbilical cord mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, and bone fractures, because MSCs can exert regenerative effects through homing to sites of damage, paracrine signaling, regulating the immune response, and affecting the microenvironment.

 

Click to Enlarge

Umbilical Cord MSCs

@ StemCells21

 

Day 13 in P1 Culture

Day 22 in P1 Culture

Day 28 in P1 Culture

100,000,000 P1 MSCs + Condition Specific RNA

6 days of supportive treatments, including laser therapy, iv nutrition, enzyme therapy, peptides and growth factors.

200,000,000 P1 MSCs + Condition Specific RNA

6 days of supportive treatments, including laser therapy, iv nutrition, enzyme therapy, peptides and growth factors.

300,000,000+ P1 MSCs + Condition Specific RNA

10 days of supportive treatments, including laser therapy, iv nutrition, enzyme therapy, peptides and growth factors.

Speak to Our Doctors